| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJHF.1790 |
| P698 | PubMed publication ID | 32212368 |
| P50 | author | John McMurray | Q56633150 |
| Jeffrey L Probstfield | Q114443555 | ||
| Jean-Claude Tardif | Q16244673 | ||
| P2093 | author name string | Eldrin F Lewis | |
| Rafael Diaz | |||
| Scott D Solomon | |||
| David Aguilar | |||
| Aldo P Maggioni | |||
| Jiankang Liu | |||
| Lars V Køber | |||
| Matthew C Riddle | |||
| Brian Claggett | |||
| Kenneth Dickstein | |||
| Hertzel C Gerstein | |||
| Sung-Hee Shin | |||
| Marc A Pfeffer | |||
| Hicham Skali | |||
| Francesca C Lawson | |||
| ELIXA Investigators | |||
| P2860 | cites work | Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial | Q45057036 |
| Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme | Q46644013 | ||
| The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis | Q47196468 | ||
| Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism | Q48887708 | ||
| Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity | Q49960457 | ||
| Suboptimal glycemic control, independently of QT interval duration, is associated with increased risk of ventricular arrhythmias in a high-risk population. | Q51280907 | ||
| Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. | Q52859591 | ||
| Impact of diabetes on cardiac structure and function: the strong heart study | Q57219886 | ||
| Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren | Q57396212 | ||
| Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes | Q57628416 | ||
| Diastolic Stiffness of the Failing Diabetic Heart | Q58087772 | ||
| The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial | Q73904927 | ||
| Effects of glucose intolerance on myocardial function and collagen-linked glycation | Q77948229 | ||
| Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction | Q80980555 | ||
| Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction | Q89748582 | ||
| 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019 | Q90595515 | ||
| Heart Failure in Type 2 Diabetes Mellitus | Q90864100 | ||
| Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure | Q93054655 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy | Q30980109 | ||
| Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction | Q33182324 | ||
| HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study | Q33766515 | ||
| Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction | Q34427866 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
| Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure | Q34815512 | ||
| Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Q35004093 | ||
| Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes | Q35051910 | ||
| Long-term prognostic importance of diabetes after a myocardial infarction depends on left ventricular systolic function | Q35123475 | ||
| Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study | Q35630009 | ||
| Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans | Q35859177 | ||
| Vascular complications of diabetes: mechanisms of injury and protective factors | Q36537262 | ||
| Diabetic cardiovascular autonomic neuropathy | Q36715017 | ||
| Diabetic cardiomyopathy revisited | Q36860318 | ||
| Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials | Q36955489 | ||
| Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations | Q37011769 | ||
| Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation | Q37241211 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| 2013 Russell Ross memorial lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus-accelerated atherosclerosis | Q37666671 | ||
| Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis | Q38055659 | ||
| Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure | Q38347423 | ||
| A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database | Q38796265 | ||
| Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial | Q39036811 | ||
| Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored | Q39209990 | ||
| Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes | Q40873421 | ||
| Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo | Q40948527 | ||
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
| The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction | Q42851023 | ||
| Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels | Q43566166 | ||
| Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment | Q44123754 | ||
| The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality | Q44520653 | ||
| P921 | main subject | acute coronary syndrome | Q266018 |
| hyperglycemia | Q271993 | ||
| ejection fraction | Q641303 | ||
| type 2 diabetes | Q3025883 | ||
| P577 | publication date | 2020-03-25 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome |
| Q97072589 | Association Between HbA1c Levels and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the TECOS Randomized Clinical Trial |
| Q99566858 | July 2020 at a glance: focus on imaging and cardiomyopathies |
| Q94469063 | The intersecting role of glycaemia and cardiac function in the development of heart failure among patients with type 2 diabetes mellitus after an acute coronary syndrome |
Search more.